COSCIENS BIOPHARMA Aktie

 

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Reconstituted Board to Revitalize COSCIENS...

TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.(“Goodwood”) regarding six (6) director nominations for the Company's upcoming Annual and Special Meeting of Shareholders....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization...

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels...

Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization...

TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announces further to its news release of March 19, 2025 (the “Default Announcement”) that its application to the Ontario Securities Commission (the “OSC”) for a management cease trade order (“MCTO”), in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), has been accepted by the OSC....

Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a d......

TORONTO, ONTARIO, March 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced Initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed for potential applications in managing conditions related to inflammation....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Continued execution on merger integration with Ceapro Inc. and advancements across business...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA0079756007 AEterna Zentaris Inc. 12.08.2024 CA22112H1010 CoSciens Biopharma Corp. 13.08.2024 Tausch 1:1 US61023L1089 Monopar Therapeutics Inc. 12.08.2024 US61023L2079 Monopar Therapeutics Inc. 13.08.2024 Tausch 5:1 DE0006967805 PRO DV AG 12.08.2024 DE000A4096T1 PRO DV AG 13.08.2024 Tausch 3:1 US89532E2081 Trevena Inc. 12.08.2024 US89532E3071 Trevena Inc. 13.08.2024 Tausch 25:1...